Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Howarth

Showing results (11-20 of 107) with videos related to

Pageof 11
Sort By:
American Journal of Respiratory and Critical Care Medicine|January 24, 2018
Rigor Is Needed When Making Comparative Analyses of Biologics in Severe AsthmaCharlene M Prazma, Rohit Katial, Peter Howarth, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|January 7, 2016
Regional assessment of lung function using thin-plate splines to align structural and functional imagingMichael J Bennett, Tom Havelock, Surussawadi Bennett, et al.
The European Respiratory Journal|October 27, 2018
Randomised controlled trials in severe asthma: selection by phenotype or stereotypeThomas Brown, Thomas Jones, Kerry Gove, et al.
Allergy|January 7, 2021
Peripheral airways type 2 inflammation, neutrophilia and microbial dysbiosis in severe asthmaAdnan Azim, Ben Green, Laurie Lau, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|September 24, 2025
Mepolizumab reduced healthcare resource utilization and improved work productivity in patients with severe asthma during the REALITI-A 2-year studyGiorgio Walter Canonica, Arnaud Bourdin, Erika Penz, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|March 10, 2022
Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptionsJohn Oppenheimer, Flavia C L Hoyte, Wanda Phipatanakul, et al.
Annals of Medicine|October 28, 2024
Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension studyIan Pavord, Robert Chan, Nicola Brown, et al.
The Journal of Allergy and Clinical Immunology|May 14, 2003
IgE to Staphylococcus aureus enterotoxins in serum is related to severity of asthmaClaus Bachert, Philippe Gevaert, Peter Howarth, et al.
Modern Rheumatology|October 15, 2025
Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: a subgroup analysis of the MARS studyTomonori Ishii, Hideaki Kunishige, Mitsuhiro Yoshida, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 21, 2025
Categorizing clinical response to mepolizumab for patients with chronic rhinosinusitis with nasal polyps: SYNAPSE trialClaire Hopkins, Larry Borish, Jared Silver, et al.
Pageof 11

Showing results (11-20 of 107) with videos related to

Sort By:
Pageof 11
American Journal of Respiratory and Critical Care Medicine|January 24, 2018
Rigor Is Needed When Making Comparative Analyses of Biologics in Severe AsthmaCharlene M Prazma, Rohit Katial, Peter Howarth, et al.
Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Annual International Conference|January 7, 2016
Regional assessment of lung function using thin-plate splines to align structural and functional imagingMichael J Bennett, Tom Havelock, Surussawadi Bennett, et al.
The European Respiratory Journal|October 27, 2018
Randomised controlled trials in severe asthma: selection by phenotype or stereotypeThomas Brown, Thomas Jones, Kerry Gove, et al.
Allergy|January 7, 2021
Peripheral airways type 2 inflammation, neutrophilia and microbial dysbiosis in severe asthmaAdnan Azim, Ben Green, Laurie Lau, et al.
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|September 24, 2025
Mepolizumab reduced healthcare resource utilization and improved work productivity in patients with severe asthma during the REALITI-A 2-year studyGiorgio Walter Canonica, Arnaud Bourdin, Erika Penz, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|March 10, 2022
Allergic and eosinophilic asthma in the era of biomarkers and biologics: similarities, differences and misconceptionsJohn Oppenheimer, Flavia C L Hoyte, Wanda Phipatanakul, et al.
Annals of Medicine|October 28, 2024
Long-term safety of mepolizumab for up to ∼10 years in patients with severe asthma: open-label extension studyIan Pavord, Robert Chan, Nicola Brown, et al.
The Journal of Allergy and Clinical Immunology|May 14, 2003
IgE to Staphylococcus aureus enterotoxins in serum is related to severity of asthmaClaus Bachert, Philippe Gevaert, Peter Howarth, et al.
Modern Rheumatology|October 15, 2025
Real-world safety and effectiveness of mepolizumab for patients with eosinophilic granulomatosis with polyangiitis in Japan: a subgroup analysis of the MARS studyTomonori Ishii, Hideaki Kunishige, Mitsuhiro Yoshida, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|June 21, 2025
Categorizing clinical response to mepolizumab for patients with chronic rhinosinusitis with nasal polyps: SYNAPSE trialClaire Hopkins, Larry Borish, Jared Silver, et al.
Pageof 11